Effect of fluoxetine and paroxetine on intestinal motility
Keywords:Diarrhea, Fluoxetine, Gastrointestinal tract, Paroxetine, Power lab, Serotonin
Background: Serotonin (5-HT) is a biogenic amine that functions as a neurotransmitter of sensorimotor functions in the digestive tract. Te role of 5-HT agents in the modulation of lower gastrointestinal function. Selective serotonin reuptake inhibitors (SSRIs) are of potential benefit in functional gastrointestinal diseases although formal evidence is lacking. Apart from central effects, they may have peripheral. The present study was carried out to find out the possible effects of fluoxetine and paroxetine on gastrointestinal smooth muscles of rabbit as they cause severe nausea and vomiting initially.
Methods: Experimental study design. Power lab (USA) for recording the contractions of ileal smooth muscle of rabbit in response to serotonin, fluoxetine and paroxetine.
Results: The percent responses with serotonin, fluoxetine and paroxetine were 100, 10.53, and 4.75 percent respectively.
Conclusions: SSRIs (fluoxetine and paroxetine) were unable to enhance the serotonergic transmission in vitro inturn decreases the qualitative response.
Gregory VC, Lucki I. The role of serotonin receptor subtypes in treating depression: A review of animal studies. Psychology. 2010;213:265-87.
Janssen P, Oudenhove VL, Castcels C, Vos R, Verbeke K, Tack J. The effect of acute citalopram dosing on gastric motor function and nutrient tolerance in healthy volunteers. Aliment Ther. 2010;33:395-402.
Mujezinovic I, Cupic V, Samajlovic A, Muminovic M. Identification of serotonergic (5-H1A-Type) receptor in broiler small intestine by application of its serotonin and antagonist. Vetnary glasnick. 2011;65(2):51-9.
Chial JH, Camilleri M, Burton D, Thomforde G, Olden WK, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal function in health. American. Journal of Physiology. Gastrointest. Liver. Physiol. 2002;284:G130-7.
Milne RJ, Goa KL. Citalopram a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drug. 1991;41(3):460-77.
Afzal A, Ajmal K, Sabeen S. Paroxetine: An update of response on intestinal motility J Pak Med Assoc. 2016 Mar;66(3):240-2.
Noor A, Najmi MH, Bakhtiar S. Effect of bradykinin induced contraction on isolated smooth muscle of guniea pig. Indian Journal of Pharmacology. 2011;43(4):449-55.
Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283:1305-22.
Afzal A, Khan BT, Sharif M. Fluoxetine causes a decrease in intestinal motility. Int J Basic Clin Pharmacol. 2015;4(2):265-8.
Coates DM, Johnson CA, Meerveld VG, Mawe MG. Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motiity. 2006;18:464-71.
Jabeen Q, Aziz N, Afzal Z, Gilani HA. The spasmogenic and spasmolytic activities of lavandula Stoechas are mediated through muscarinic receptor stimulation and calcium channel blockade. International Journal of Pharmacoogyl. 2007;3(1):61-7.
James BR. Acetylcholine. Wormbook. Ed. The elegans Research Community. 2007.
Pithadia BA, Jain MS. 5-Hydroxytryptamine Receptor Subtypes and their modulation with Therpeutic Potentials. J of clinical Medicines Res. 2009;(1):72-80.
Spiller R. Serotonergic modulating drugs for functional gastrointestinal diseases. British Journal of Pharmacology. 2002;54:11-20.
Tanko Y, Alladey O, Ahmad KM, Muhammad A, Musa KY. The effect of methanol leaves extract of Ficus Glumosa on gastrointestinal motility and castor oil induced diarrhoe in laboratory animals. Scholar research library. 2012;2(3):360-7.
Tuladhar RB, Costall B, Naylor JR. Modulation of 5-HT4 receptor function in the rat isolated ileum by fluoxetine: the involvement of endogenous 5-Hydroxytryptamine. British Journal of Pharmacology. 2002;136:150-6.
Wagstaff AJ, Cheer SM, Matheson AJ, Ormvod D, Goa KL. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002;62(4):655-703.